vaccin
one
success
breakthrough
medic
histori
recent
year
epitopebas
subunit
vaccin
introduc
safer
altern
tradit
vaccin
howev
suffer
limit
immunogen
nanotechnolog
shown
valu
solv
issu
differ
kind
nanovaccin
employ
among
viruslik
nanoparticl
vlp
selfassembl
peptid
nanoparticl
sapn
seem
promis
recent
sapn
attract
special
interest
due
uniqu
properti
includ
molecular
specif
biodegrad
biocompat
also
resembl
pathogen
term
size
multival
allow
orderli
repetit
display
antigen
surfac
induc
stronger
immun
respons
singl
immunogen
vaccin
design
sapn
selfadjuvant
regard
outstand
advantag
sinc
use
toxic
adjuv
longer
requir
sapn
usual
compos
helic
secondari
structur
tailor
natur
peptid
de
novo
structur
flexibl
subunit
select
open
door
wide
varieti
molecul
differ
characterist
sapn
engin
emerg
area
novel
structur
expect
gener
futur
particularli
rapid
progress
relat
comput
tool
aim
review
provid
stateoftheart
overview
selfassembl
peptid
nanoparticl
use
vaccin
design
recent
studi
addit
principl
design
applic
comput
approach
vaccin
design
summar
vaccin
one
success
breakthrough
medic
histori
recent
year
epitopebas
subunit
vaccin
introduc
safer
altern
tradit
vaccin
howev
suffer
limit
immunogen
nanotechnolog
shown
valu
solv
issu
differ
kind
nanovaccin
employ
among
viruslik
nanoparticl
vlp
selfassembl
peptid
nanoparticl
sapn
seem
promis
recent
sapn
attract
special
interest
due
uniqu
properti
includ
molecular
specif
biodegrad
biocompat
also
resembl
pathogen
term
size
multival
allow
orderli
repetit
display
antigen
surfac
induc
stronger
immun
respons
singl
immunogen
vaccin
design
sapn
selfadjuvant
regard
outstand
advantag
sinc
use
toxic
adjuv
longer
requir
sapn
usual
compos
helic
secondari
structur
tailor
natur
peptid
de
novo
structur
flexibl
subunit
select
open
door
wide
varieti
molecul
differ
characterist
sapn
engin
emerg
area
novel
structur
expect
gener
futur
particularli
rapid
progress
relat
comput
tool
aim
review
provid
stateoftheart
overview
selfassembl
peptid
nanoparticl
use
vaccin
design
recent
studi
addit
principl
design
applic
comput
approach
vaccin
design
summar
hundr
year
vaccin
one
success
strategi
combat
differ
infecti
diseas
consequ
decreas
morbid
mortal
among
human
toth
edward
jenner
first
vaccin
smallpox
jenner
found
inocul
pu
cowpox
lesion
handmaid
hand
patient
infect
smallpox
confer
immun
stern
markel
aim
everi
vaccin
present
particular
antigen
set
antigen
immun
system
order
elicit
immun
pathogen
addit
effici
elicit
immun
respons
ideal
vaccin
safe
show
longterm
stabil
ambient
temperatur
demonstr
high
popul
coverag
provid
protect
administr
singl
dose
moreov
manufactur
purif
character
process
effect
requir
minim
number
step
afford
enabl
broad
vaccin
use
oldest
type
vaccin
tradit
vaccin
consist
either
live
attenu
kill
microorgan
inactiv
toxin
skwarczynski
toth
develop
vaccin
use
whole
organ
effect
elicit
longlast
innat
adapt
immun
respons
karch
burkhard
despit
benefit
tradit
vaccin
disadvantag
risk
infect
probabl
allerg
autoimmun
reaction
difficulti
relat
cultur
product
stabil
moreov
develop
diseas
cancer
sever
infecti
diseas
therefor
new
type
vaccin
name
subunit
vaccin
develop
mani
advantag
compar
whole
organismbas
vaccin
includ
lack
pathogen
organ
safeti
eas
product
stabil
low
allerg
autoimmun
respons
henc
vaccin
consid
effici
toth
base
mention
merit
mani
research
includ
team
work
extens
develop
type
vaccin
farhadi
et
al
hajighahramani
et
al
mahmoodi
et
al
nezafat
et
al
nezafat
et
al
nezafat
et
al
shahbazi
et
al
subunit
vaccin
contain
antigen
fragment
pathogen
frequent
proteinbas
antigen
capabl
stimul
appropri
adapt
immun
respons
limit
name
instabl
product
complex
low
puriti
importantli
induct
autoimmun
respons
observ
frequent
proteinbas
subunit
vaccin
epitopebas
subunit
vaccin
therefor
epitopebas
subunit
vaccin
often
prefer
compos
multipl
individu
antigen
epitop
one
sever
pathogen
azmi
et
al
nezafat
et
al
skwarczynski
toth
epitop
usual
consist
bcell
epitop
helper
tcell
th
epitop
cytotox
tcell
ctl
epitop
bind
bcell
receptor
bcr
bcell
epitop
activ
two
way
presenc
th
cell
tcellindepend
manner
gener
tcellindepend
pathway
activ
bcell
produc
longlast
bcell
respons
first
step
type
tcell
epitop
process
antigenpres
cell
apc
includ
dendrit
cell
dc
macrophag
bcell
exogen
particl
toxin
bacteri
pathogen
locat
cell
surfac
process
present
th
cell
major
histocompat
complex
ii
mhcii
afterward
activ
th
cell
directli
indirectli
stimul
bcell
ctl
promot
secret
cytokin
chemokin
therefor
activ
th
cell
stimul
adapt
immun
innat
immun
respons
endogen
particl
viral
particl
cancer
cell
locat
cytosol
process
present
ctl
mhci
activ
ctl
kill
intracellular
pathogen
tumor
cell
induc
cellmedi
immun
moyl
toth
skwarczynski
toth
thu
design
epitopebas
subunit
vaccin
research
must
identifi
tcell
bcell
epitop
induc
appropri
immun
respons
howev
low
immunogen
major
drawback
type
vaccin
thu
due
lack
whole
organ
abil
vaccin
stimul
immun
respons
much
weaker
tradit
vaccin
differ
approach
appli
boost
immunogen
subunit
vaccin
includ
administr
multipl
dose
vaccin
patient
life
longlast
protect
use
adjuv
employ
nanotechnolog
approach
ie
design
nanovaccin
moyl
toth
adjuv
addit
compon
vaccin
stimul
apc
target
innat
immun
system
way
induc
robust
immun
respons
foge
adjuv
classifi
three
group
deliveri
system
compos
nonimmunostimulatori
compon
target
present
vaccin
immun
system
immunostimul
pathogenassoci
molecular
pattern
pamp
directli
stimul
innat
immun
system
combin
two
mention
class
highest
effici
foge
moyl
toth
mani
research
group
attempt
develop
effect
adjuv
adjuv
use
vaccin
product
due
sever
disadvantag
includ
low
safeti
high
toxic
adjuv
approv
use
human
aluminum
salt
alum
first
approv
widelyus
adjuv
oilinwat
emuls
virosom
formul
monophosphoryl
lipid
mpl
alum
foge
karch
burkhard
one
promis
area
rapidli
gain
attent
use
nanotechnolog
vaccin
develop
yang
et
al
zhao
et
al
consid
one
effect
strategi
conquer
low
immunogen
epitopebas
vaccin
nanovaccin
new
class
vaccin
develop
incorpor
epitop
nanoparticl
microscop
particl
least
one
dimens
nm
size
high
surfac
area
volum
ratio
horikoshi
serpon
srirajaskanthan
preedi
vaccin
highli
efficaci
mimic
featur
pathogen
size
shape
pamp
approach
shown
improv
antigen
stabil
immunogen
function
moreov
nanovaccin
act
deliveri
system
target
site
diseas
bodi
instead
organ
addit
use
prevent
treat
differ
diseas
particularli
cancer
stimul
humor
cellmedi
respons
sekhon
saluja
yang
et
al
nanovaccin
classifi
sever
group
accord
type
nanoparticl
appli
structur
shown
fig
differ
approv
investig
nanoparticlebas
nanovaccin
summar
tabl
nanoparticl
function
deliveri
system
use
formul
differ
drug
vaccin
stabil
bodi
protect
antigen
degrad
agent
control
releas
antigen
slow
biodegrad
rate
biolog
properti
includ
target
encapsul
antigen
carri
target
cell
ie
immun
cell
among
type
nanoparticl
polylact
acid
pla
chitosan
poli
lactidecoglycolid
acid
plga
poli
glutam
acid
pga
polypeptid
polyethylen
glycol
copolym
typic
polym
howev
plga
appli
encapsul
antigen
differ
pathogen
plasmodium
vivax
hepat
b
viru
hbv
bacillu
anthraci
pga
use
entrap
hydrophob
antigen
two
wide
use
polym
due
biocompat
biodegrad
azmi
et
al
skwarczynski
toth
zhao
et
al
recent
thermorespons
synthet
polym
trp
nanoparticl
base
nisopropylacrylamid
nipam
n
methacrylamid
hpma
polym
abl
selfassembl
immunogen
particl
physiolog
temperatur
develop
codeliveri
toll
like
receptor
agonist
adjuv
immunogen
respiratori
syncyti
viru
rsv
fusion
f
protein
trimer
trp
nanoparticl
induc
broadbas
humor
cellular
immun
respons
moreov
stabl
solubl
filter
colloid
dispers
unimolecular
purif
storag
phase
francica
et
al
lynn
et
al
current
variou
vaccin
base
polymer
nanoparticl
test
preclin
clinic
trial
treatment
differ
diseas
human
immunodefici
viru
hiv
cancer
tuberculosi
bolhassani
et
al
tabl
synthet
nanoparticl
also
appli
deliveri
system
frequent
nonbiodegrad
inorgan
nanoparticl
extens
use
vaccin
formul
appropri
physicochem
properti
includ
porou
rigid
structur
control
synthesi
surfac
function
differ
ligand
gold
silver
ferric
oxid
alumina
nanoparticl
carbon
nanotub
exampl
inorgan
nanoparticl
easili
convert
desir
shape
size
gold
nanoparticl
wide
use
vaccin
deliveri
compar
nanoparticl
exampl
gold
nanoparticl
exploit
develop
vaccin
rsv
infect
influenza
hiv
footandmouth
diseas
conjug
absorb
antigen
surfac
karch
burkhard
skwarczynski
toth
zhao
et
al
nanoparticl
encapsul
antigen
within
core
deliv
target
cell
lipid
lead
format
amphiphil
improv
diffus
across
epitheli
barrier
provid
stabil
degrad
agent
golkar
et
al
golkar
et
al
zhao
et
al
structur
target
vaccin
dc
stimul
activ
cell
selfadjuv
properti
lipidbas
nanoparticl
may
differ
structur
emuls
includ
oilinwat
waterinoil
form
immunostimul
complex
iscom
cagelik
lipid
particl
zhao
et
al
liposom
golkar
et
al
tavakoli
et
al
among
three
type
liposom
broadli
use
compos
biodegrad
nontox
natur
synthet
bilay
phospholipid
surround
aqueou
core
azmi
et
al
vaccin
formul
antigen
determin
often
peptidebas
antigen
integr
within
lipid
bilay
liposom
protect
enzymat
degrad
moreov
liposomeantigen
complex
effici
stimul
cellular
immun
respons
natur
therefor
liposomebas
structur
potenti
effici
vaccin
adjuv
azmi
et
al
toth
current
sever
liposom
vaccin
test
clinic
studi
tabl
viruslik
nanoparticl
vlp
one
type
selfassembl
protein
discuss
separ
due
viral
origin
specif
conform
fact
vlp
recombin
selfassembl
capsid
protein
ideal
diamet
nm
noninfecti
nonrepl
therefor
appli
effect
diagnost
approach
drug
dna
peptid
protein
vaccin
deliveri
vaccin
deliveri
varieti
differ
antigen
genet
chemic
fuse
vlp
present
surfac
vlp
strongli
stimul
immun
system
without
need
adjuv
mimic
structur
nativ
virus
azmi
et
al
yang
et
al
fact
vlp
induc
innat
immun
respons
activ
tlr
pattern
recognit
receptor
prr
well
humor
immun
respons
particularli
igm
due
particul
natur
vlp
also
increas
uptak
antigen
apc
current
approv
vlpbase
vaccin
avail
market
includ
recombin
hepat
b
viru
vaccin
human
papilloma
viru
vaccin
sever
vlp
vaccin
also
test
clinic
trial
differ
diseas
shirbaghae
bolhassani
tabl
anoth
method
develop
effect
epitopebas
nanovaccin
use
selfassembl
peptid
nanoparticl
sapn
sapn
typic
peptid
helic
secondari
structur
assembl
togeth
noncoval
interact
form
nanos
tubular
fibrillar
spheric
structur
fujita
taguchi
jung
et
al
use
sapn
potenti
vaccin
platform
discuss
detail
subsequ
section
introduct
selfassembl
peptid
nanoparticl
concept
selfassembl
selfassembl
defin
abil
molecul
spontan
arrang
wellord
structur
whitesid
grzybowski
natur
common
phenomenon
result
product
varieti
ensembl
use
finit
build
block
indelicato
et
al
whitesid
grzybowski
natur
selfassembl
molecul
primarili
compos
dna
polypeptid
protein
found
wide
varieti
live
organ
viru
capsid
cell
membran
enzym
cellular
cytoskeleton
molecul
involv
divers
rang
sophist
cellular
function
includ
transport
motil
storag
cellular
morpholog
base
specif
shape
small
size
physicochem
mechan
featur
howorka
simpl
fact
underli
selfassembl
molecul
reach
stabl
compat
structur
lower
energi
level
selfassembl
occur
variou
attractiverepuls
forc
within
molecul
balanc
mandal
et
al
lead
format
numer
differ
noncoval
weak
interact
hydrogen
bond
electrostat
hydrophob
van
der
waal
interact
webber
et
al
watermedi
hydrogen
bond
also
import
biolog
system
molecul
primarili
contact
water
weak
minor
interact
lead
format
supramolecul
specif
conform
shape
interact
structur
molecul
zhao
zhang
first
exampl
natur
selfassembl
particl
protein
deriv
virus
tobacco
mosaic
viru
tmv
capsid
hepat
b
viru
hbv
surfac
antigen
hbsag
fact
first
hbv
vaccin
licens
develop
base
vlp
nanoparticl
obtain
virus
et
al
molecular
engin
protein
monomer
build
block
selfassembl
first
suggest
drexler
foresaw
develop
advanc
molecular
machineri
construct
devic
materi
atom
precis
base
bright
new
idea
sinc
selfassembl
peptid
employ
produc
broad
rang
materi
nanofib
yanlian
et
al
zhang
nanowir
sun
et
al
nanor
carlson
et
al
shah
et
al
nanotub
hartgerink
et
al
scanlon
agg
nanoparticl
kaba
et
al
raman
et
al
among
other
may
also
form
order
nanoscal
structur
mesoscop
macroscop
level
whitesid
grzybowski
includ
monolay
hydrogel
threedimension
scaffold
mimick
selfassembl
concept
natur
structur
enabl
scientist
build
divers
selfassembl
nanomateri
four
biomolecul
class
peptid
lipid
nucleic
acid
sugar
differ
size
scale
broad
rang
applic
biomedicin
environment
scienc
inform
technolog
materi
scienc
busseron
et
al
zhao
zhang
peptid
selfassembl
nanostructur
use
peptid
surfact
mandal
et
al
zhao
zhang
membran
separ
purif
busseron
et
al
research
model
protein
fold
protein
conform
diseas
studi
addit
enzym
immobil
blood
cell
substitut
doll
et
al
zhao
zhang
nanoscal
selfassembl
peptid
possess
central
caviti
enabl
carri
drug
gene
use
control
drug
releas
gene
drug
deliveri
doll
et
al
habibi
et
al
sapn
also
har
cellcultur
repar
regen
medicin
tissu
engin
pharmacolog
antagonist
imag
biosensor
diagnost
devic
develop
busseron
et
al
habibi
et
al
hauser
zhang
also
shown
antimicrobi
anticanc
activ
studi
roy
et
al
one
promis
applic
sapn
vaccin
develop
kaba
et
al
zhang
et
al
zhao
et
al
discuss
next
section
sapn
usual
consist
seri
repetit
motif
enabl
incorpor
epitop
antigen
subunit
structur
way
incorpor
molecul
display
surfac
assembl
particl
therebi
build
chimer
sapn
use
adjuv
adjuvantcarri
vaccin
two
structur
featur
sapn
molecular
specif
multival
make
suitabl
vaccin
adjuv
carrier
high
antigen
densiti
structur
order
antigen
arrang
sapn
resembl
recognit
pattern
pathogen
thu
facilit
crosslink
antigen
bcr
et
al
multival
interact
key
step
provok
potent
immun
respons
solut
weak
immunogen
subunit
vaccin
fact
sapn
elicit
high
titer
high
affin
neutral
igg
addit
tcellmedi
protect
chesson
et
al
trigger
complement
activ
also
help
creat
microenviron
promot
interact
vaccin
apc
eskandari
et
al
hubbel
et
al
therefor
sapn
use
prophylact
immunotherapeut
vaccin
hubbel
et
al
incorpor
antigen
selfassembl
peptid
subsequ
product
chimer
sapn
accomplish
direct
selfassembl
process
coval
chemic
bond
antigen
nanoparticl
et
al
sapn
coiledcoil
structur
studi
sever
group
vaccin
carrier
andor
adjuv
el
bissati
et
al
karch
burkhard
howev
research
need
develop
effici
vaccin
adjuv
emerg
area
mechan
action
mani
adjuv
yet
clear
shah
et
al
mani
question
remain
best
paramet
ideal
adjuv
particl
size
oyewumi
et
al
question
add
complex
studi
sapn
vaccin
despit
conflict
regard
optimum
size
nanoparticl
suitabl
vaccin
adjuv
particl
diamet
nm
seem
suitabl
effect
interact
differ
cell
immun
system
bachmann
jen
oyewumi
et
al
despit
selfadjuvant
sapn
employ
vaccin
adjuv
includ
tlr
agonist
also
investig
tlr
categori
prr
recogn
pamp
bacteria
virus
therebi
trigger
innat
immun
system
promot
antigen
process
apc
therefor
tlr
agonist
recent
introduc
effici
vaccin
adjuv
reed
et
al
agonist
use
adjuv
develop
hiv
vaccin
selfassembl
peptid
platform
tlr
agonist
coassembl
peptid
anoth
studi
polyi
c
polyinosin
polycytidyl
acid
agonist
incorpor
novel
vaccin
construct
immun
polyelectrolyt
multilay
ipem
capsul
electrostat
assembl
entir
peptid
antigen
molecular
adjuv
without
polym
chiu
et
al
use
adjuv
vaccin
develop
sapn
platform
also
evalu
instanc
addit
freund
adjuv
sapn
vaccin
avian
influenza
infect
elicit
higher
antibodi
titer
babapoor
et
al
howev
studi
employ
sapn
alon
adjuv
suffici
promot
immun
respons
context
peptid
hydrogel
adjuv
antigen
vaccin
develop
west
nile
viru
induc
stronger
immun
respons
confer
protect
compar
alum
adjuv
friedrich
et
al
fabric
sapn
special
interest
due
uniqu
potenti
nanostructur
advanc
sapn
synthesi
delay
sever
year
due
complex
design
molecular
assembl
howev
addit
continu
develop
comput
tool
novel
idea
recent
help
research
make
consider
progress
area
king
lai
creation
complex
structur
highli
order
repetit
limit
number
build
block
fascin
featur
selfassembl
sapn
fabric
bottomup
approach
lakshmanan
et
al
begin
select
peptid
build
block
subunit
need
proper
masteri
molecular
structur
build
block
assembl
tendenc
zhang
primari
secondari
structur
peptid
control
selfassembl
properti
instanc
exact
structur
coiledcoil
parallel
antiparallel
orient
dimer
tetram
predict
base
sequenc
ramisch
et
al
furthermor
noncoval
interact
among
main
side
chain
atom
lead
gener
secondari
structur
ultim
drive
format
structur
sapn
fairman
akerfeldt
yang
et
al
peptid
build
block
borrow
natur
molecul
synthes
novel
comput
sequenc
design
brunett
et
al
common
subunit
oligomer
motif
observ
natur
protein
coil
burkhard
et
al
lupa
conveni
build
block
design
sapn
due
stabil
welldefin
structur
doll
et
al
yang
et
al
coiledcoil
broadli
use
vaccin
develop
hudalla
et
al
rudra
et
al
rudra
et
al
rudra
et
al
discuss
detail
next
section
selfassembl
similar
subunit
natur
almost
alway
follow
central
rule
symmetri
rational
behind
phenomenon
foreseen
watson
crick
watson
fewer
definit
kind
specif
interact
interfac
need
symmetr
assembl
compar
asymmetr
assembl
lai
et
al
key
rule
immens
simplifi
process
design
sapn
base
assumpt
build
block
ident
structur
interact
particip
shape
homomer
complex
moreov
number
potenti
structur
limit
symmetri
rule
follow
fig
avid
second
govern
characterist
selfassembl
enabl
format
stabl
complex
base
weak
interact
among
build
block
norn
exampl
homomer
icosahedr
protein
capsid
avid
induc
stabil
valu
six
order
magnitud
higher
affin
among
individu
symmetr
build
block
mateu
norn
avid
concept
help
design
higherord
assembl
use
comput
tool
ideal
architectur
design
sapn
depend
intend
usag
exampl
hollow
core
shell
structur
like
cage
desir
drug
gene
deliveri
mask
shield
molecul
manner
compact
structur
repetit
unit
excel
candid
present
multipl
copi
antigen
vaccin
chemic
applic
elsawi
et
al
raman
et
al
sanner
et
al
notabl
selfassembl
usual
dynam
equilibrium
occur
forward
revers
direct
seem
control
kinet
instead
thermodynam
marsh
et
al
norn
hydrophobichydrophil
balanc
key
player
peptid
selfassembl
mandal
et
al
regard
vaccin
activ
peptid
antigen
usual
hydrophil
zhao
et
al
parker
et
al
therefor
hydrophil
part
sapn
ideal
region
epitop
carriag
hand
adjuv
primarili
hydrophob
liu
et
al
hydrophob
portion
may
trigger
innat
immun
system
seong
matzing
thu
dual
natur
sapn
favor
vaccin
function
differ
method
employ
creat
drive
forc
need
selfassembl
list
tabl
three
key
aspect
consid
design
selfassembl
molecul
subunit
conform
subunit
interact
regul
assembl
king
lai
two
basic
strategi
adopt
design
sapn
oligomer
fusion
interfac
design
lai
et
al
fig
oligomer
fusion
method
oligom
build
block
fuse
togeth
form
differ
structur
interfac
design
approach
newer
method
evolv
along
accumul
research
knowledg
first
approach
improv
comput
algorithm
enjoy
advantag
accur
control
interfac
geometri
lead
higher
structur
order
moreov
proteinprotein
interfac
control
assembl
stabil
quaternari
structur
sapn
norn
natur
number
interfac
depend
symmetri
stoichiometri
similar
monom
ardejani
orner
wherea
structur
result
protein
close
relat
assembl
pathway
marsh
et
al
structur
one
interfac
compos
monom
includ
cyclic
fibril
intern
symmetri
cyclic
symmetr
build
block
gener
complex
symmetr
structur
two
interfac
dihedr
cubic
lattic
design
three
interfac
monom
shape
crystal
complex
structur
norn
sapn
synthesi
highli
depend
select
proper
build
block
discuss
exampl
artifici
natur
sapn
polar
hydrophob
amino
acid
locat
altern
pattern
mandal
et
al
selfassembl
occur
spontan
unit
condit
appropri
gener
principl
follow
vaccin
develop
base
sapn
platform
epitop
would
also
incorpor
sapn
structur
either
linker
direct
attach
one
approach
synthes
sapn
system
first
follow
function
epitop
proper
condit
achiev
vaccin
construct
friedrich
et
al
rudra
et
al
use
method
epitop
coval
attach
termini
present
surfac
peptid
nanofib
preserv
immunogen
elicit
high
antibodi
titer
cellular
respons
mice
without
need
adjuv
branco
et
al
altern
peptid
monom
includ
selfassembl
domain
epitop
may
produc
express
recombin
protein
escherichia
coli
host
selfassembl
product
el
bissati
et
al
kaba
et
al
pimentel
et
al
selfassembl
peptid
may
synthes
alon
tandem
epitop
via
solid
phase
peptid
synthesi
method
high
puriti
coin
et
al
rudra
et
al
amino
acid
pair
aap
strategi
also
use
sapn
synthesi
method
base
three
major
interact
hydrogen
bond
electrostat
attract
hydrophob
interact
creat
amino
acid
side
chain
selfassembl
peptid
adjac
peptid
molecul
eskandari
et
al
fung
et
al
although
approach
use
fabric
fibril
drug
deliveri
sadatmousavi
may
also
appli
vaccin
design
three
major
type
symmetri
use
sapn
fig
discuss
next
section
categori
subunit
stabil
fuse
repeat
protein
coval
bond
repeat
assembl
form
open
linear
structur
helic
curvatur
close
ring
structur
rotat
symmetri
gener
sapn
class
may
also
possess
structur
broom
et
al
longo
et
al
nd
voet
et
al
tim
barrel
mani
structur
either
natur
synthet
scaffold
repeat
protein
may
gener
gene
duplic
fusion
singl
repeat
geometr
constraint
linear
repeat
protein
lower
cyclic
protein
moreov
adopt
variou
supramolecular
form
may
exist
natur
norn
supramolecular
shape
control
either
comput
de
novo
design
brunett
et
al
doyl
et
al
park
et
al
use
slightli
differ
oligomer
repeat
produc
structur
predefin
geometri
molecular
architectur
ramisch
et
al
addit
differ
conform
repeat
may
use
gener
structur
nonuniform
curvatur
park
et
al
larg
protein
complex
close
symmetri
gener
cyclic
symmetr
build
block
polyhedr
structur
usual
cagelik
hollow
center
icosahedr
arrang
ubiquit
among
spheric
viru
capsid
zandi
et
al
imit
stabl
model
mani
studi
doll
et
coiledcoil
helic
bundl
interact
peptid
contain
pentamer
trimer
coiledcoil
domain
antigen
display
icosahedron
icosahedron
stabl
well
defin
oligom
buffer
condit
impact
assembl
affect
noncoval
interact
oligom
engin
disulfid
bond
docecahedr
structur
filament
consist
symmetr
homooligomer
protein
multipl
heterointeract
protein
bind
element
stabil
selfassembl
particl
disulfid
bond
lock
system
favor
format
proper
assembl
intermolecular
disulfid
bond
avoid
raman
et
al
usui
et
al
metalmedi
interact
nanotub
crystallin
array
monomer
protein
subunit
symmetr
own
properli
orient
metal
coordin
motif
surfac
brodin
et
al
chemic
crosslink
quadrat
network
tetramer
aldolas
product
protein
network
adjust
mesh
network
assembl
sensit
inhomogen
subunit
ringler
schulz
genet
fusion
multipl
protein
domain
fragment
natur
selfassoci
tetrahedr
sapn
consist
two
oligom
link
helic
linker
product
wide
varieti
highli
symmetr
structur
extend
materi
oligom
begin
end
ahelix
symmetri
rule
fix
geometr
relationship
two
symmetri
axe
follow
oligom
match
rotat
symmetri
key
role
linker
design
sapn
fold
unlik
natur
structur
obtain
helixloop
repeat
unit
limit
straight
rod
helixloophelixloop
subunit
adopt
brunett
et
al
highli
repetit
geometri
icosahedron
similar
viru
capsid
make
ideal
repetit
antigen
display
consequ
trigger
high
antibodi
titer
sanner
et
al
cubic
symmetri
fabric
use
two
previous
mention
approach
oligomer
fusion
interfac
design
fusion
approach
linker
sequenc
usual
polypeptid
need
join
oligomer
domain
togeth
rel
rigid
fix
way
obtain
regular
selfassembl
structur
padilla
et
al
fig
otherwis
oligomer
unit
may
adopt
differ
orient
lead
irregular
assembl
gener
epitop
vaccin
linker
short
sequenc
sensit
proteasom
degrad
nezafat
et
al
commonli
use
two
reason
separ
antigen
domain
arai
et
al
prevent
gener
junction
epitop
neoepitop
promot
process
present
hlaii
bind
epitop
sapn
differ
type
linker
employ
architectur
purpos
accord
desir
structur
lai
et
al
interfac
design
approach
commonli
design
cage
homomer
norn
howev
protein
cage
tetrahedr
octahedr
symmetri
comput
design
use
trimer
oligom
introduct
singl
new
interfac
high
accuraci
recent
tetrahedr
cage
design
two
distinct
oligom
singl
interfac
king
et
al
divers
combin
built
two
build
block
open
possibl
develop
wide
varieti
sapn
differ
characterist
applic
openend
assembl
includ
fibril
lattic
nanoscal
proteinprotein
interact
link
mesoscal
properti
materi
norn
fibril
fabric
monom
singl
selfcompat
interfac
gener
fronttoend
assembl
norn
report
product
antifreez
amyloid
fiber
peralta
et
al
howev
mani
natur
protein
fiber
present
complex
structur
engin
fibril
one
interfac
usual
associ
anoth
motif
structur
limit
number
avail
interfac
grigoryan
et
al
kaltofen
et
al
design
lattic
similar
cubic
symmetri
common
oligom
use
case
cyclic
symmetri
fusion
approach
interfac
design
employ
symmetr
crystal
extend
lattic
engin
monomer
oligom
requir
least
three
interfac
norn
gener
import
factor
consid
sapn
synthesi
regardless
classif
describ
basic
peptid
build
block
synthes
two
main
approach
recombin
technolog
solid
phase
chemic
method
habibi
et
al
chemic
method
may
use
synthes
short
peptid
wherea
recombin
technolog
ration
choic
product
complex
peptid
chain
howev
ferment
cost
control
requir
addit
difficulti
detect
impur
purif
challeng
consid
particularli
largescal
product
requir
chemic
method
build
block
sequenc
buffer
condit
may
affect
molecular
weight
produc
sapn
polymorph
indelicato
et
al
nanoscal
assembl
base
fundament
paramet
peptid
solut
concentr
anoth
factor
influenc
selfassembl
sapn
ph
determin
overal
charg
differ
oligom
therebi
affect
sapn
format
doll
et
al
common
issu
fabric
sapn
method
use
studi
success
solut
briefli
describ
tabl
current
vaccinolog
integr
immunolog
system
biolog
immunoinformat
structur
biolog
nanotechnolog
scienc
like
piec
puzzl
put
togeth
develop
effici
vaccin
bioinformat
provid
great
help
research
aim
gener
predict
perform
lab
experi
design
sapn
similar
field
negahdaripour
et
al
rahmatabadi
et
al
zamani
et
al
help
save
time
energi
rahmatabadi
et
al
hand
use
comput
tool
vaccin
design
sapn
develop
seem
unavoid
consid
huge
volum
data
must
compil
sapn
design
usual
begin
initi
comput
design
calcul
expect
molecular
mass
diamet
symmetri
advanc
past
year
factor
impact
design
complex
rotat
translat
degre
freedom
marsh
et
al
differ
compet
assembl
state
similar
stabil
fleishman
baker
ramisch
et
al
also
calcul
comput
howev
deviat
predict
model
report
brunett
et
al
take
advantag
molecular
model
simul
program
variou
oligomer
domain
combin
design
novel
selfassembl
nanoparticl
sanner
et
al
moreov
point
mutat
within
oligomer
domain
adjac
linker
within
linker
impact
assembl
investig
program
ardejani
orner
addit
protein
stabil
optim
comput
program
modifi
surfac
polar
core
hydrophob
backbon
regular
netzer
fleishman
interfac
design
comput
challeng
task
achiev
geometr
precis
interfac
lai
et
al
howev
great
headway
recent
made
area
netzer
fleishman
gener
comput
method
use
design
sapn
interfac
design
explain
includ
two
step
symmetr
dock
protein
build
block
target
symmetr
architectur
design
lowenergi
proteinprotein
interfac
build
block
promot
selfassembl
protein
assembl
predict
sever
differ
comput
tool
usual
base
two
main
approach
templatebas
model
includ
homolog
model
thread
free
model
exampl
sever
tool
includ
rosetta
leaverfay
et
al
cabsfold
blaszczyk
et
al
falcon
use
de
novo
protein
predict
server
tool
improv
constantli
protein
structur
predict
center
http
predictioncenterorg
biennial
perform
object
test
abil
server
identifi
protein
structur
sequenc
process
blind
predict
support
improv
method
recent
publish
result
critic
assess
tabl
main
issu
sapn
fabric
appli
solut
control
limit
assembl
aggreg
undesir
extens
nanoparticl
result
polydispers
structur
charg
repuls
ntermini
helic
subunit
fletcher
et
al
cap
oligom
lack
bind
element
necessari
assembl
end
subunit
usui
et
al
larg
aggreg
inclus
bodi
form
subunit
linkag
insid
host
cell
separ
product
compon
subunit
differ
bacteri
strain
mix
purifi
solubl
compon
situ
afterward
ringler
schulz
sinclair
et
al
usui
et
al
addit
metal
ligand
trigger
assembl
mix
solut
discret
subunit
brodin
et
al
carlson
et
al
lai
et
al
reach
oligomer
specif
biophys
challeng
exist
compet
oligomer
state
slight
differ
energi
gap
isoenerget
energi
level
avoid
kinet
trap
aggreg
assembl
process
exampl
combin
de
novo
structur
model
stabil
calcul
simultan
predict
structur
oligomer
state
homomer
coiledcoil
marsh
et
al
norn
ramisch
et
al
protein
structur
predict
casp
experi
casp
publish
protein
journal
oct
dec
issu
lensink
et
al
monastyrskyy
et
al
ovchinnikov
et
al
outcom
await
sapn
categor
differ
perspect
base
indic
shape
cagelik
lattic
nanofib
etc
build
block
structur
cyclic
alphahelix
ardejani
orner
kim
et
al
build
block
sourc
natur
ab
initio
design
design
approach
mani
featur
review
focus
common
subunit
use
build
sapn
includ
coiledcoil
usag
vaccin
linu
paul
robert
corey
california
institut
technolog
herman
branson
present
structur
along
seri
eight
paper
submit
pna
suggest
model
deduc
characterist
smaller
molecul
eisenberg
explain
second
paper
hydrogenbond
layer
structur
polypeptid
chain
altern
chain
opposit
orient
also
introduc
pleat
sheet
form
hydrogenbond
layer
structur
polypeptid
chain
chain
similarli
orient
call
structur
second
structur
identifi
ie
identifi
first
one
common
natur
motif
util
creat
selfassembl
peptid
habibi
et
al
peptid
compos
altern
hydrophil
charg
polar
hydrophob
uncharg
nonpolar
amino
acid
repeat
provid
backbon
amphiphil
properti
possess
tendenc
form
structur
one
hydrophil
face
one
hydrophob
face
doll
et
al
eskandari
et
al
habibi
et
al
zhang
et
al
amino
acid
arrang
promot
hydrogen
bond
among
residu
hydrogen
donor
acceptor
variou
polypeptid
chain
differ
part
fold
polypeptid
result
parallelantiparallel
sheetlik
structur
eskandari
et
al
two
sheet
interact
surround
aqueou
media
contact
hydrophil
face
sheet
wherea
aqueou
media
exclud
hydrophob
face
doll
et
al
motif
use
fabric
supramolecular
structur
variou
hierarch
structur
array
develop
base
number
pack
sheet
tape
ribbon
fibril
fiber
fig
eskandari
et
al
kumar
et
al
loo
et
al
howev
physiolog
condit
short
peptid
primarili
selfassembl
nanofib
doll
et
al
rudra
et
al
initi
selfassembl
regul
introduct
stimuli
phosphatebuff
salin
pb
ph
chang
bowerman
nilsson
chen
sun
et
al
peptid
primarili
selfassembl
dissolv
aqueou
solut
allow
fibril
overnight
low
concentr
wv
mechan
characterist
selfassembl
control
adjust
molar
ratio
enantiomer
peptid
differ
ratio
lpeptid
compos
lamino
acid
dpeptid
compos
damino
acid
appli
design
selfassembl
structur
use
chiral
peptid
sequenc
may
greatli
enhanc
stabil
prepar
peptid
scaffold
protect
enzymat
degrad
eskandari
et
al
nagi
et
al
furthermor
polypeptid
rich
alanin
glycin
g
form
larger
beta
strand
zhang
et
al
variou
selfassembl
peptid
physicochem
characterist
present
tabl
physicochem
properti
peptid
calcul
use
protparam
tool
http
webexpasyorgprotparam
server
gasteig
et
al
filament
particl
abl
increas
drug
bioavail
increas
circul
time
maximum
toler
dose
promot
tumor
cell
apoptosi
delay
clearanc
drug
liver
spleen
particip
fewer
interact
serum
protein
due
neutral
charg
surfac
eskandari
et
al
lee
et
al
peptid
selfassembl
studi
less
extens
coiledcoil
peptid
selfassembl
howev
sever
selfassembl
peptid
investig
vaccinerel
research
natur
protein
selfassembl
water
util
peptid
motif
peptid
scaffold
accident
discov
initi
attempt
earli
first
member
class
discov
yeast
protein
zuotin
zhang
et
al
selfassembl
peptid
name
util
codeliveri
tcell
epitop
agonist
conjug
cytotox
lymphocyt
ctl
epitop
peptid
selfassembl
nanofib
aqueou
solut
ex
vivo
produc
dendrit
cell
patient
treat
nanofib
stimul
ctl
cell
treat
either
alon
mixtur
tlr
agonist
furthermor
develop
nanofib
induc
stronger
ctl
respons
vaccin
mice
one
wellstudi
nanofib
consist
amino
acid
abil
selfassembl
unbranch
antiparallel
collier
messersmith
jung
et
al
karch
burkhard
schemat
represent
nanofib
selfassembl
fibril
domain
conjug
b
bowerman
nilsson
ding
et
al
hong
et
al
loo
et
al
zhang
et
al
zhang
et
al
zhang
et
al
bowerman
nilsson
loo
et
al
zhang
et
al
zhang
et
al
bowerman
nilsson
caplan
et
al
continu
next
page
cell
epitop
peptid
shown
fig
studi
perform
rudra
colleagu
fibril
peptid
acqqkfqfqfeqqam
fkfefkf
use
develop
selfadjuv
vaccin
deliveri
system
peptid
antigen
coval
conjug
nterminu
nonimmunogen
amphipath
fibril
peptid
model
produc
nanoparticl
absenc
adjuv
system
result
strong
longlast
antibodi
respons
addit
conjug
assembl
rich
nanofib
aqueou
buffer
lead
higher
titer
anticocain
antibodi
vaccin
mice
without
need
adjuv
tlr
ligand
respons
often
associ
inflammatori
signal
omit
selfadjuv
vaccin
use
approach
seem
promis
one
investig
peptid
domain
qqkfqfqfeqq
conjug
model
peptid
antigen
ovalbumin
result
conjug
vaccin
selfassembl
nanofib
water
physiolog
buffer
shown
noncytotox
vitro
lack
sever
import
featur
vivo
quantifi
inflamm
swell
site
inject
accumul
either
inflammatori
cytokin
cell
gener
allerg
ige
respons
furthermor
prepar
nanofib
show
strong
antibodi
respons
mice
tcelldepend
vaccin
abl
produc
strong
tcell
respons
effect
infecti
diseas
cancer
anoth
studi
chesson
colleagu
conjug
ova
tcell
ovalbumin
epitop
result
peptid
conjug
selfassembl
nanofib
induc
strong
tcell
respons
moreov
selfassembl
vaccin
abl
protect
repeat
influenza
viru
infect
vaccin
regimen
remark
nanofib
accumul
site
inject
inflammatori
antigen
deposit
chesson
et
al
design
antimalaria
vaccin
epitop
plasmodium
falciparum
circumsporozoit
protein
nanp
attach
selfassembl
peptid
investig
immunogen
mechan
qualiti
antibodi
respons
nanp
conjug
selfassembl
nanofib
notabl
increas
antibodi
titer
signific
inhibit
sporozoit
infect
produc
prepar
selfassembl
nanofib
antibodi
respons
tcelland
furthermor
two
differ
epi
tope
selfassembl
togeth
without
impact
strength
durat
antibodi
respons
develop
nanofib
propos
favor
platform
selfadjuv
multiantigen
immunotherapi
karch
burkhard
rudra
et
al
anoth
kind
selfadjuv
peptid
nanofib
produc
coassembl
common
highaffin
tcell
epitop
name
padr
bcell
epitop
staphylococcu
aureu
conjug
peptid
increas
padr
concentr
result
bellshap
dose
respons
distinct
variou
popul
tcell
interestingli
epitop
ratio
maxim
follicular
helper
antibodi
respons
differ
order
magnitud
ratio
maxim
respons
karch
burkhard
pompano
et
al
studi
perform
friedrich
et
al
adjuv
potenti
peptid
hydrogel
examin
use
model
peptid
combin
immunoprotect
envelop
protein
domain
iii
eiii
west
nile
viru
wnv
protect
subunit
antigen
mous
model
vaccin
wnv
eiii
emulsifi
peptid
hydrogel
eiii
gener
strong
antibodi
respons
significantli
protect
mous
model
lethal
infect
compar
wnv
eiii
adjuv
alum
eiii
alum
impli
peptid
hydrogel
adjuv
might
viabl
altern
alum
produc
protect
immun
peptid
use
applic
addit
vaccin
also
possess
variou
featur
peptid
may
also
potenti
vaccin
develop
futur
exampl
briefli
present
effect
function
peptid
hydrophob
face
selfassembl
band
gelat
evalu
investig
perform
elsawi
cowork
selfassembl
peptid
fefkfefkk
util
studi
form
stabl
fiber
hydrogel
elsawi
et
al
agg
et
al
develop
class
selfassembl
peptid
name
klealvyvlgfftlgimlsyir
form
nanotap
selfassembl
regular
nanofib
anoth
report
peptid
gnndesnisfkek
structur
form
nanofib
morpholog
compris
twist
tape
structur
concentr
greater
critic
aggreg
concentr
wt
chen
studi
sadatmousavi
investig
abil
selfassembl
complementari
peptid
structur
stabil
anticanc
drug
ellipticin
vitro
therapeut
efficaci
system
determin
like
coiledcoil
structur
discov
william
astburi
earli
astburi
astburi
appli
first
xray
diffract
measur
natur
protein
fiber
keratin
wool
horsehair
collagen
discov
three
main
structur
nativ
wool
aform
denatur
form
bform
collagen
astburi
observ
meridion
arc
propos
may
deform
coiledcoil
clarifi
reflect
meridian
indic
energi
involv
deform
like
small
crick
l
paul
caltech
usa
l
bragg
cambridg
uk
attempt
interpret
meridion
arc
observ
paul
corey
year
l
paul
r
corey
h
branson
caltech
usa
elabor
mathemat
model
residu
per
turn
residu
per
turn
structur
l
paul
r
corey
caltech
usa
separ
submit
report
natur
show
diffract
pattern
attribut
pack
two
strand
crick
paul
corey
subsequ
crick
describ
fourier
transform
continu
coiledcoil
domain
followup
paper
explain
knobsinhol
configur
lead
pack
form
coiledcoil
apostolov
et
al
crick
crick
crick
paul
corey
coiledcoil
structur
common
proteinfold
motif
garner
particular
attent
due
relationship
threedimension
structur
peptid
amino
acid
sequenc
primari
analysi
differ
protein
sequenc
predict
protein
residu
possess
coiledcoil
motif
burkhard
et
al
pechar
pola
robson
marsden
kro
coiledcoil
consist
two
peptid
wrap
around
superhel
fashion
produc
stabl
complex
aqueou
solut
major
peptid
form
coiledcoil
structur
base
heptad
repeat
repetit
seven
amino
acid
residu
heptad
repeat
pattern
form
abcdefg
n
n
number
heptad
repeat
hydrophob
amino
acid
often
locat
posit
wherea
hydrophil
amino
acid
place
e
g
posit
parri
et
al
pechar
pola
robson
marsden
kro
number
helic
superhelix
determin
select
hydrophob
amino
acid
residu
posit
hydrophob
core
coiledcoil
describ
tight
pack
hydrophob
amino
acid
side
chain
knobsinhol
fashion
ionic
interact
residu
posit
e
g
two
helic
significantli
contribut
stabil
coiledcoil
motif
pechar
pola
seven
main
factor
influenc
stabil
coiledcoil
includ
hydrophob
core
residu
posit
number
heptad
repeat
abcdefg
n
helix
melt
temperatur
high
thermal
stabil
high
bind
constant
result
reduc
immunogen
lower
synthesi
cost
ph
chang
ph
induc
unfold
coiledcoil
de
proton
side
chain
function
group
amino
acid
residu
e
g
follow
disrupt
interchain
salt
bridg
destabil
coiledcoil
specif
interstrand
interact
disulfid
bridg
metal
ion
import
direct
protein
fold
stabil
tertiari
structur
electron
transfer
mainli
influenc
orient
helic
coiledcoil
helic
propens
amino
acid
residu
remain
posit
apostolov
et
al
amino
acid
sequenc
determin
mani
aspect
coiledcoil
bind
stabil
direct
bind
parallel
antiparallel
oligomer
state
two
peptid
size
nm
long
rigid
homomer
heteromer
bind
robson
marsden
kro
coiledcoil
domain
cartilag
oligomer
matrix
protein
comp
malashkevich
et
al
tetrabrachion
stetefeld
et
al
fibritin
tao
et
al
leucin
zipper
oshea
et
al
wellknown
exampl
coiledcoil
repres
pentamer
tetramer
trimer
dimer
coiledcoil
respect
coiledcoil
motif
common
natur
protein
fold
motif
tabl
contrast
de
novo
coiledcoil
tabl
use
produc
peptideprotein
hybrid
materi
de
novo
coiledcoil
novel
welldefin
structur
properti
control
via
engin
proteinpeptid
primari
structur
apostolov
et
al
pechar
pola
coiledcoil
protein
particularli
heterodimer
coiledcoil
differ
applic
de
novo
coiledcoilbas
biomaterialshybrid
includ
hybrid
hydrogel
fig
yang
et
al
drugdeliveri
fig
hodg
hodg
colleagu
use
ek
coiledcoil
compos
homotetram
antiparallel
handel
et
al
homodim
homotrim
switch
parallel
gonzalez
et
al
monera
et
al
zhou
et
al
e
k
peptid
immobil
protein
surfac
plasmon
reson
spr
sensor
chip
apostolov
et
al
chao
et
al
k
peptid
compos
five
heptad
repeat
sequenc
kvsalk
e
peptid
consist
number
heptad
repeat
sequenc
evsalek
gabcdef
hydrophob
residu
posit
interact
mainli
respons
format
stabil
coiledcoil
one
studi
rang
epitop
obtain
synthet
peptid
antipseudomona
aeruginosa
pa
vaccin
immobil
ek
coiledcoil
spr
sensor
chip
character
accord
affin
crossreact
varieti
antibodi
cachia
et
al
chao
et
al
burkhard
group
construct
selfassembl
peptid
exploit
multipl
antigendisplay
platform
base
pentamer
coiledcoil
oligomer
domain
deriv
cartilag
oligomer
matrix
protein
comp
de
novo
minim
trimer
coiledcoil
oligomer
domain
group
use
platform
present
bcell
immunodomin
repeat
epitop
dppppnpn
deriv
circumsporozoit
protein
malaria
parasit
plasmodium
berghei
surfac
sapn
construct
comp
structur
known
administr
vaccin
formul
complet
freund
adjuv
cfa
success
gener
high
antibodi
titer
protect
mice
malaria
challeng
six
month
conjug
malaria
vaccin
preclin
evalu
usa
shown
studi
burkhard
cowork
deliveri
phosphatebuff
salin
pb
induc
longliv
protect
immun
respons
mice
without
need
heterolog
adjuv
schemat
display
peptid
nanoparticl
selfassembl
pentamer
trimer
coiledcoil
domain
conjug
b
cell
epitop
peptid
repres
fig
moreov
immun
gener
tcelldepend
antibodi
promot
protect
kaba
et
al
anoth
studi
kaba
et
al
construct
vaccin
pfcspsapn
vaccin
base
sapn
display
bcell
tcell
epitop
deriv
circumsporozoit
protein
csp
plasmodium
falciparum
pfcsp
human
malaria
parasit
vaccin
induc
product
epitopespecif
antibodi
longliv
polyfunct
produc
central
memori
tcell
protect
mice
lethal
dose
transgen
p
berghei
express
csp
p
falciparum
furthermor
pfcspsapn
vaccin
consider
protect
cultur
human
hepatocyt
invas
growth
nativ
p
falciparum
wahom
et
al
develop
hiv
vaccin
use
nanoparticl
compos
two
coval
link
coiledcoil
domain
join
membran
proxim
extern
region
mper
howev
vaccin
abl
gener
antibodi
although
nanoparticl
induc
high
mperspecif
titer
none
sera
exhibit
notic
neutral
activ
pimentel
et
al
design
produc
prototyp
sar
sever
acut
respiratori
syndrom
vaccin
induc
neutral
negahdaripour
et
al
biotechnolog
advanc
antibodi
sar
viru
epitop
vitro
sar
vaccin
construct
insert
trimer
coiledcoil
epitop
hrc
ctermin
heptad
repeat
sarscov
viru
spike
protein
sapn
sar
nanoparticl
evok
specif
neutral
antibodi
trimer
coiledcoil
epitop
hrc
mice
babapoor
et
al
devis
two
novel
vaccin
immun
chicken
avian
influenza
ai
base
insert
monomer
tetramer
form
immunogen
epitop
extern
domain
avian
influenza
viru
matrix
protein
sapn
vaccin
rais
igg
respons
vaccin
chicken
specif
pathogenfre
chicken
compar
nonvaccin
group
use
adjuv
vaccin
construct
induc
consider
higher
antibodi
respons
raman
et
al
prepar
nm
diamet
regular
polyhedr
peptid
nanoparticl
coval
bond
coiledcoil
peptid
elicit
immun
respons
peptid
chain
nanoparticl
consist
two
coiledcoil
oligomer
domain
form
peptid
nanoparticl
diamet
approxim
nm
aqueou
solut
polyhedr
peptid
nanoparticl
suitabl
drug
target
drug
deliveri
system
repetit
antigen
display
applic
el
bissati
et
al
produc
novel
selfassembl
nanoparticl
platform
deliv
peptid
epitop
evok
tcell
toxoplasma
gondii
infect
sapn
platform
compos
dens
granul
lpqfataat
peptid
linear
peptid
lp
monom
contain
two
coiledcoil
oligomer
domain
univers
tcell
epitop
deriv
padr
padr
sapn
induc
protect
immun
gondii
hlab
transgen
mice
nanoscal
size
sapn
make
similar
pathogen
cordeiro
et
al
moreov
morpholog
shape
repetit
structur
multival
howorka
allow
condens
antigen
similar
pamp
microb
lead
recognit
prp
activ
immun
system
rudra
et
al
antigen
attach
posit
well
control
addit
sapn
biocompat
biodegrad
deriv
protein
main
build
block
live
organ
sanner
et
al
differ
unit
held
togeth
weak
interact
instead
chemic
coval
bond
one
signific
challeng
vaccin
design
creat
maintain
balanc
immunogen
inflamm
mainli
vaccin
incorpor
proinflammatori
adjuv
aluminum
hydroxid
al
oh
aluminum
phosphat
microparticl
even
tlr
agonist
selfadjuvant
sapn
allow
vaccin
develop
incorpor
adjuv
key
benefit
consid
possibl
inflamm
toxic
caus
adjuv
recent
interest
develop
nonparenter
vaccin
emerg
due
differ
advantag
includ
usag
conveni
complianc
greater
number
patient
lack
need
profession
administ
inject
econom
advantag
sapn
candid
vaccin
carrier
formul
context
sapn
contain
squalenyl
deriv
known
possess
excel
oral
bioavail
studi
develop
oral
dosag
form
fondaparinux
anticoagul
low
oral
bioavail
ralayranaivo
et
al
similar
approach
employ
oral
vaccin
deliveri
gener
benefici
characterist
sapn
import
applic
includ
vaccin
design
report
sapn
chemic
well
defin
manufactur
sun
et
al
addit
speed
protein
express
purif
selfassembl
nanoparticl
lead
accept
cost
time
need
largescal
product
sapn
babapoor
et
al
kaba
et
al
product
process
environment
friendli
involv
use
larg
amount
chemic
zhao
et
al
overal
sapn
fabric
afford
lack
complex
bottom
approach
zhao
zhang
advantag
sapn
includ
stabil
high
temperatur
resist
enzymat
degrad
organ
solvent
extrem
ph
valu
roy
et
al
well
symmetr
natur
modular
respons
stimuli
bioactiv
chemic
divers
possibl
structur
design
engin
match
specif
need
fairman
akerfeldt
lead
versatil
mandal
et
al
merit
word
sapn
synthes
varieti
natur
nonnatur
amino
acid
build
block
divers
characterist
webber
et
al
sever
special
featur
sapn
make
superior
nano
system
use
vaccin
develop
exampl
mechan
chemic
stabil
sapn
consid
import
advantag
liposom
raman
et
al
biodegrad
primari
advantag
sapn
synthet
nanoparticl
carrier
polym
polymer
reaction
may
lead
gener
sever
product
variou
length
molecular
weight
moreov
reaction
polym
epitop
sometim
result
structur
differ
degre
substitut
zhao
et
al
toxic
immunogen
polym
carrier
use
micel
yet
thoroughli
studi
concern
vaccin
develop
yokoyama
gener
sapn
prefer
structur
contain
lipid
due
potenti
toxic
lipopeptid
risk
membran
disrupt
addit
lipidbas
nanostructur
strong
induc
cellular
immun
respons
zhao
et
al
hand
concern
regard
sapn
persist
stabil
liquid
environ
accur
size
control
fabric
given
divers
sapn
immunogen
featur
studi
type
sapn
although
sapn
shown
toxic
cell
longterm
effect
investig
habibi
et
al
subunit
epitopebas
vaccin
develop
overcom
safeti
concern
regard
use
tradit
vaccin
howev
increas
safeti
new
vaccin
advers
affect
immunogen
lead
requir
adjuv
usag
suscept
enzymat
degrad
anoth
issu
vaccin
recent
nanotechnolog
employ
vaccin
develop
augment
vaccin
immunogen
stabil
sapn
shown
benefit
nanostructur
system
use
vaccin
develop
usag
vaccin
design
emerg
due
advantag
multival
biodegrad
biocompat
molecular
specif
orderli
repetit
array
antigen
sapn
structur
small
size
resembl
pamp
lead
strong
immun
reaction
sapn
vaccin
mainli
construct
coiledcoil
biostructur
motif
immunodomin
band
tcell
epitop
variou
antigen
protect
bacteria
virus
fuse
control
condit
coiledcoil
assembl
singl
nanoparticl
varieti
form
structur
act
carrier
immun
adjuv
enhanc
humor
cellular
immun
selfadjuv
properti
consid
key
benefit
sapn
allow
use
vaccin
without
unwant
inflammatori
side
effect
toxic
adjuv
sapn
promis
candid
adjuvantscarri
vaccin
includ
nonparenter
formul
despit
outstand
recent
advanc
sapn
design
deeper
understand
selfassembl
phenomenon
factor
influenc
process
ration
design
principl
requir
produc
peptid
nanoparticl
favor
characterist
challeng
design
function
fabric
sapn
persist
context
achiev
control
specif
size
monodispers
product
import
due
key
role
uptak
antigen
apc
consequ
induct
immun
respons
solidphas
method
usual
allow
size
synthes
peptid
control
increas
stabil
sapn
wider
ph
rang
anoth
concern
moreov
detail
studi
relat
physicochem
morpholog
featur
sapn
biolog
immunolog
activ
need
addit
coiledcoil
current
use
vaccin
develop
research
novel
architectur
introduc
combin
structur
coiledcoil
hybrid
found
natur
helixloophelixloop
repetit
structur
special
featur
potenti
differ
desir
characterist
may
achiev
select
appropri
build
subunit
identifi
repeat
protein
motif
minor
part
probabl
structur
mani
possibl
explor
use
synthet
biolog
regard
silico
model
assist
discoveri
novel
selfassembl
peptid
appropri
structur
effect
thousand
avail
natur
peptid
ab
initio
design
build
block
substanti
increas
opportun
develop
novel
sapn
howev
immunogen
novel
synthet
oligom
care
test
architectur
assembl
pathway
investig
control
achiev
higher
success
rate
accur
sapn
design
addit
specif
oligomer
improv
use
immunoinformat
select
immunodomin
epitop
addit
structur
biolog
comput
model
achiev
desir
biomolecul
may
also
help
continu
progress
improv
comput
algorithm
would
undeni
support
process
overal
sapn
usag
vaccin
design
seem
promis
combin
mention
knowledg
may
lead
exploit
auspici
potenti
sapn
vaccin
manufactur
success
transit
clinic
use
futur
author
declar
conflict
interest
